[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563524":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":48,"collaborators":50,"id":53,"slug":20,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":20,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":75,"whyStopped":20,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"New York Medical College","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CD30 CAR T-cells","EXPERIMENTAL","Patients will receive autologous CD30 CAR T-cells post autologous stem cell transplant between days 21-42.",[13],"Biological: CD30 CAR T-cell",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","CD30 CAR T-cell","After MAC and AutoHSCT patients will receive CD30+ CAR T-cells (Phase 1B dose level 1 - 1x108\u002Fm2 (max 2.5x108) or dose level 2 - 2x108\u002Fm2 (max 5.0 x108) 21-42 days after the AutoHSCT and the RP2D dose level obtained in the Phase IB part administered in the Phase II portion.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Mitchell S Cairo, MD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","914-594-2150","mitchell_cairo@nymc.edu",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Lauren Harrison, MSN","617-285-7844","lauren_harrison@nymc.edu",[35],{"facility":5,"status":20,"city":36,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Valhalla","New York","10595","United States",{"type":41,"coordinates":42},"Point",[43,44],-73.77513,41.07482,{"lat":44,"lon":43},[47],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"type":49,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[51],{"name":52,"class":6},"University of North Carolina","100563524",false,"NCT06617286","CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma","MAC-CAR: A Phase 1B\u002FII Trial of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Autologous CD30+ CAR T Cells in Children, Adolescents and Young Adults With Poor-Risk Classical Hodgkin Lymphoma (cHL)","Inclusion Criteria:\n\n* Age between ≥ 6 and ≤ 29.99 years at the time of consent.\n* Lansky OR Karnofsky score of ≥ 60% (see Appendix VI)\n* Disease Status: Confirmed diagnosis of CD30+ classical Hodgkin Lymphoma and meets eligibility to undergo ASCT. Must meet one of the following:\n\nInduction failure Progressive disease Disease relapse (1st, 2nd or 3rd)\n\n* Confirmatory re-biopsy of relapse\u002Frefractory\u002Fpersistent CD30+ cHL prior to study entry.\n* Risk Factors: Patient must meet 2 or more of the established risk factors:\n\nPerformance score (Karnofsky\u002FLansky) \\\u003C;90% Time from diagnosis to first relapse of \\\u003C1 year Extra nodal involvement at the time of relapse\u002Fprogression High baseline metabolic tumor volume (MTV, \\>60mL) by 18F-fluorodeoxyglucose positron emission tomography (PET)\u002Fcomputed tomography (CT) Chemo resistant disease (Deauville 4-5) after the first re-induction\n\nExclusion Criteria:\n\n* not meeting the inclusion criteria","ALL","6 Years","29 Years",{"count":63,"type":64},21,"ESTIMATED","INTERVENTIONAL",[67,68],"PHASE1","PHASE2","Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.",[71],"Classical Hodgkin Lymphoma",[73,74],"classical Hodgkin lymphoma","CAR T-cells","NOT_YET_RECRUITING","2026-04-10",{"date":78,"type":79},"2026-04-15","ACTUAL",{"date":81,"type":64},"2026-12-01",{"date":83,"type":64},"2040-12-31",{"name":5,"class":6},1]